Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and
safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma
patients who have progressed after at least one line of platinum-based chemotherapy for
advanced disease without having received any previous immunotherapy (previous bevacizumab
allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or
radiotherapy, regardless of PD-L1 status.